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Summary Objectives: Currently, two intradermal regimens for the administration
of cell culture rabies vaccines are approved by the WHO for rabies post-exposure
prophylaxis: the two site Thai Red Cross regimen (TRC) and the eight site regimen.
For the TRC regimen the volume of vaccine recommended per dose is 0.1ml of puri-
ﬁed Vero cell rabies vaccine (PVRV) and 0.2ml of puriﬁed chick embryo cell vaccine
(PCEC). The objective of the present study was to evaluate comparatively the im-
mune response to PCEC and PVRV vaccines administered by the TRC regimen using a
uniform dose of 0.1ml of vaccine.
Methods: Forty-two subjects received TRC regimen (2-2-2-0-1-1) with 0.1ml of
PCEC vaccine and 38 subjects received the same regimen with PVRV. The rabies neu-
tralizing antibody response in these subjects on days 10, 28, 90 and 180 was deter-
mined by the standard mouse neutralization test (MNT).
Results: There was adequate antibody response with both the vaccines and 100%
seroconversion was observed by day 10. Furthermore, the antibody titers obtained
with PCEC did not differ signiﬁcantly from those obtained with PVRV on all days tested
(p > 0.05).
Conclusions: It can be concluded from the results that an adequate antibody re-
sponse can be obtained with PCEC vaccine when administered by the TRC regimen
even after reducing the quantity of vaccine from 0.2ml to 0.1ml per intradermal
dose. The feasibility of using this regimen in true post-exposure cases needs to be
further evaluated.
© 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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Introduction
Dog bites, post-exposure vaccination and human
deaths due to rabies are signiﬁcant health prob-
lems in developing countries, including India. The
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World Health Organization (WHO) estimates that
around 50,000 rabies deaths are currently re-
ported every year, with India alone accounting for
30,000 deaths.1 Nearly two million people receive
post-exposure vaccination in India, which has an
estimated dog population of 20 million.2
Recently, some Asian countries including Sri
Lanka and Thailand have signiﬁcantly reduced ra-
bies deaths in humans mainly due to the discontin-
uation of the Semple vaccine and the introduction
of a cost-effective intradermal (ID) vaccination
with highly potent and safe cell culture vaccines.
At present, three types of cell culture rabies vac-
cines are available in India i.e. the puriﬁed chick
embryo cell vaccine (PCEC); the puriﬁed Vero cell
rabies vaccine (PVRV) and the human diploid cell
vaccine (HDCV). However, conventional intramus-
cular (IM) dosage schedules with these vaccines will
not be affordable for the majority of the exposed
people.
An economical ID vaccination for post-exposure
prophylaxis was approved by the WHO in 19923
and subsequently endorsed in 1996.4 Two regimens
were approved. i.e. the Thai Red Cross regimen
(TRC) in which 1/5 of the IM dose of either PVRV or
PCEC is administered ID on days 0, 3, 7, and on days
28 and 905 and an eight site regimen (applicable to
only PCEC and HDCV) in which 0.1ml of vaccine is
administered at eight sites on day 0, at four sites
on day 7 and at one site on days 28 and 90.6 As per
these recommendations, in the TRC regimen, one
has to administer either 0.1ml PVRV or 0.2ml of
PCEC per dose. Subsequent to these recommenda-
tions, some studies in Thailand demonstrated the
immunogenicity, safety and efﬁcacy of the PCEC
vaccine when administered in a 0.1ml (1/10 of IM
dose) dose using the TRC regimen.7—9 If the PCEC
vaccine is administered under this regimen, it will
become more economical than PVRV, as the total
quantity of vaccine in a single vial after reconstitu-
tion is 1ml and hence twice the number of patients
can be vaccinated in comparison to PVRV.
The WHO expert committee meeting held in June
2000 recommended this regimen for national au-
thorities to consider but also cautioned that more
data need to be generated.10 The immunogenicity
of such a regimen using a reduced quantity of the
PCEC vaccine in the Indian population has not been
reported so far. India is currently on the threshold of
introducing ID regimens in major anti-rabies treat-
ment centres across the country and data from such
studies will become important.
Keeping this in view we administered the PCEC
vaccine under this regimen to 42 healthy people
who needed pre-exposure prophylaxis and evalu-
ated the immune response in comparison to the
response observed in 38 people who were adminis-
tered PVRV under the same TRC regimen.
Materials and methods
Subjects
Forty-two people working in the Infectious Diseases
Hospital in Bangalore, and 38 people working in the
neurological intensive care units of the National In-
stitute of Mental Health & Neurosciences (NIMHANS)
in Bangalore who were likely to treat patients with
rabies were included, as they needed pre-exposure
rabies prophylaxis. Of these, 42 people (21 adult
males and 21 adult females, age range 21—49 years,
mean age 32 years) were immunized with the PCEC
vaccine and 38 (20 adult males and 18 adult fe-
males, age range 25—52 years, mean age 30 years)
were immunized with the PVRV vaccine. All the sub-
jects in the PCEC group were from the Infectious
Diseases Hospital, while subjects in the PVRV group
belonged to NIMHANS. All were recruited during the
same period and all were physically healthy and
were not taking any medication.
Vaccines and regimen
The PCEC vaccine (Rabipur®, Chiron Vaccines,
batch No. 653, potency >2.5 IU) and the PVRV vac-
cine (Verorab, Aventis Pasteur, batch No. U 1240,
potency >2.5 IU) were used in this study. The vac-
cines were reconstituted with 1ml of sterile water
for injection in the case of PCEC and 0.5ml in the
case of PVRV and inoculated in a 0.1ml dose ID
on two sites (over upper arm) on day 0, 3 and 7
and at one site on day 28 and 90. As subjects were
vaccinated in groups, the diluted vaccine was used
at one time and there was no wastage of vaccine.
Each subject was inoculated with a separate 1 ml
disposable insulin syringe. The subjects were inter-
rogated and physically examined on each occasion
for evidence of any side-effects. Blood samples
were collected on day 0 (prior to immunization)
and on days 10, 28, 90 and 180 after immunization.
Estimation of antibody titers
The rabies neutralizing antibody titers in the serum
samples were estimated by the mouse neutral-
ization test (MNT) as advocated by the WHO.11
The challenge virus standard (CVS 11) used in the
test was obtained from the Central Research Insti-
tute, Kasauli. The antibody titers of serum samples
were expressed in International Units (IU/ml) as
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compared to an in-house reference serum previ-
ously calibrated against second international stan-
dard of anti-rabies immunoglobulin serum with a
known potency of 30 IU (obtained from National In-
stitute for Biological Standards and Control, NIBSC,
UK). The in-house reference serum was prepared
from immunized rabbits and was calibrated by the
MNT in parallel with the international standard.
The antibody titer of the in-house reference serum
was determined after running duplicate tests. This
in-house reference serum has 15 IU/ml of potency
in comparison to the international standard. For
conducting MNT, prior permission from the insti-
tutional animal ethics committee was obtained
and the experimental mice were caged and looked
after as per the guidelines in force.
Statistical analysis
The neutralizing antibody titers observed in the two
groups were expressed as arithmetic means with
standard deviations. The difference in the antibody
titers observed in the two groups was analyzed by
using a Student’s t-test.
Results
None of the serum samples had detectable antibody
titer on day 0 prior to vaccination. There were two
dropouts after the 2nd dose of the vaccination in
the PCEC group because these subjects were unex-
pectedly deputed to another hospital.
Blood samples were obtained from 40 people on
day 10, 38 people on days 28 and 90 and 35 people
on day 180 in the PCEC group. In the PVRV group
blood samples were obtained from 38 people on day
10, 35 people on days 28 and 90 and 33 people on
day 180. The antibody titers observed with the two
vaccines are reported in Table 1. It is evident that
there was 100% seroconversion in both the groups
Table 1 Mean neutralizing antibody titers (IU/ml) to the rabies virus in subjects vaccinated with the PCEC vaccine
and the PVRV vaccine using the TRC (2-2-2-0-1-1) regimen.
Vaccine and subjects Neutralizing antibody titers (IU/ml)a on days
10 28 90 180
PCEC
Subjects (n = 42) 5.8 (± 3.1) 10.9 (± 4.1) 13.1 (± 3.9) 5.7 (± 3.1)
PVRV
Subjects (n = 38) 5.9 (± 3.2) 12.1 (± 4.5) 14.3 (± 2.7) 5.9 (± 2.5)
a Mean titers (± standard deviation). PCEC: Puriﬁed chick embryo cell vaccine. PVRV: Puriﬁed Vero cell rabies
vaccine. TRC: Thai Red Cross regimen.
Table 2 Side-effects observed with the PCEC vac-
cine and the PVRV administered by the TRC regimen.
Side-effectsa Type of vaccine
PCEC PVRV
Pain 4/42 (9.5%) 2/24 (8.3%)
Itching 3/42 (7.1%) 2/24 (8.3%)
Erythema 2/42 (4.8%) 1/24 (4.2%)
Induration 2/42 (4.8%) 1/24 (4.2%)
Fever 1/42 (2.4%) 0/24
Arthralgia 1/42 (2.4%) 0/24
PCEC: Puriﬁed chick embryo cell vaccine. PVRV: Puri-
ﬁed vero cell rabies vaccine.
a Side-effects observed on days 3 and 7.
by day 10. Moreover, the antibody titers with the
two vaccines on all days tested did not differ signif-
icantly (p>0.05) with titers considerably above the
minimum required titer of 0.5 IU/ml of serum on
all days tested. There were minor side-effects such
as local erythema, itching and induration observed
with both the vaccines on day 3 and 7 (Table 2).
However these were self-limiting and required no
treatment.
Discussion
The current rabies vaccines prevent rabies in ex-
posed persons by the induction of neutralizing
antibodies.12 The amount and speed of antibody
induction is crucial for disease prevention. The
WHO has recommended a minimum antibody titer
of 0.5 IU/ml of serum for protection against this
disease.3 Studies conducted so far have clearly
indicated that all the ID regimens recommended
can induce antibody titers considerably above the
minimum required for protection. The initial doubt
as to whether a reduced volume (0.1ml instead
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of 0.2ml) of PCEC vaccine can induce protective
antibody levels if given by the TRC regimen is now
resolved as evidenced by the results of studies
conducted in Thailand7—9 and the present study
reported here on Indian subjects. As the results of
the present study indicate, 100% seroconversion
was evident on day 10 and protective titers were
present even six months later. The titers obtained
with PCEC vaccine did not differ signiﬁcantly from
those obtained with PVRV vaccine (p>0.05). The
side-effects observed were negligible and did not
require any treatment (Table 2).
Administration of 0.2ml of the PCEC vaccine
by the ID route as recommended previously may
pose practical difﬁculties as it tends to be more
painful and the bleb formed is much larger. The
alternative recommendation was to give two ID
inoculations of 0.1ml in nearby sites. However, in-
oculating 0.1ml ID at two nearby sites means more
injection pricks to the patient, causing more pain
and inconvenience. These practical difﬁculties may
be overcome if this newly-approved regimen is
practiced.
The currently available cell culture vaccines are
not economical if regular IM regimens are used. For
instance, the total cost per patient of the vaccine
alone is around Rs. 1,500 (US$ 30) with the use of
PVRV and PCEC, which may be unaffordable by the
majority of exposed people. If these vaccines are
used ID the cost per patient will reduce to Rs 400
(US$ 8). Although the Semple vaccine is cheaper,
the actual expenditure per patient may work out to
be more than the cost of administration of cell cul-
ture vaccines by the intradermal route, if the indi-
rect cost in terms of the number of man days lost,
serious side-effects and cost of their management
are also added. In a recent estimate, the cost of
the Semple vaccine being administered in govern-
ment hospitals and dispensaries worked out to be
about Rs 200 (US$ 4.5) per patient, which is half
the cost of PVRV if administered by the TRC regi-
men. On the other hand, if the volume per dose of
the PCEC vaccine is reduced from 0.2ml (as rec-
ommended previously) to 0.1ml as recommended
now, the cost per patient will work out at even less
than the cost of the Semple vaccine. Therefore a
highly potent and safe vaccine can be administered
instead of the outdated and unsafe Semple vaccine,
whose production was recommended to be discon-
tinued more than a decade ago by the WHO. There-
fore there is an urgent need to phase out the Sem-
ple vaccine and introduce these cost-effective ID
regimens.
One of the major drawbacks of abbreviated ID
regimens is the possible wastage of reconstituted
vaccine if it cannot be distributed amongst pa-
tients within six hours. However, a recent study
in Thailand has demonstrated that the reconsti-
tuted vaccine can be stored for up to seven days
at 4 ◦C in a refrigerator without loss of potency
or fear of contamination.13 However, wastage of
reconstituted vaccine may not be encountered in
major anti-rabies clinics and dispensaries where
a large number of patients attend on any single
day.
Conclusion
To conclude, this simulated post-exposure study
with the PCEC vaccine administered by the WHO-
recommended TRC regimen using 0.1ml per ID dose
proved to be as immunogenic and as safe as the
TRC regimen with PVRV in Indian subjects. It is now
planned to extend this study to people exposed to
rabies by animal bites so that data on the efﬁcacy
of this regimen can be generated.
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